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Background: Direct-acting antiviral (DAA) agents target HCV proteins; some of these have already been approved
for the treatment of HCV infection, while others are in development. However, selection of DAA-resistant viral
variants may hamper treatment. The aim of this study was to illustrate potential natural DAA-resistance mutations in
the HCV NS5A and NS5B regions of HCV genotypes 1a and 1b from DAA-naïve patients.
Methods: Direct sequencing of HCV NS5A and NS5B regions was performed in 32 patients infected with HCV
genotype 1a and 30 patients infected with HCV genotype 1b; all subjects were naïve to DAAs.
Results: In genotype 1a strains, resistance mutations in NS5A (M28V, L31M and H58P) were observed in 4/32
(12.5%) patients, and resistance mutations in NS5B (V321I, M426L, Y448H, Y452H) were observed in 4/32 (12.5%)
patients. In genotype 1b, resistance mutations in NS5A (L28V, L31M, Q54H, Y93H and I280V) were observed in 16/30
(53.3%) patients, while resistance mutations in NS5B (L159F, V321I, C316N, M426L, Y452H, R465G and V499A) were
observed in 27/30 (90%) patients.
Conclusions: Mutations conferring DAA resistance were detected in NS5A and NS5B of HCV genotypes 1a and 1b
from DAA-naïve patients. Although some mutations confer only a low level of resistance, the presence at baseline
of mutated HCV variants should be taken into consideration in the context of DAA therapy.
Keywords: Hepatitis C virus, HCV baseline resistance, NS5A and NS5B genes, DAA inhibitorsBackground
Hepatitis C virus (HCV) is classified into six genotypes
(1–6) and more than 100 subtypes. The most common
genotypes in Western countries are 1a and 1b [1].
Peginterferon/ribavirin (PegIFN/RBV) for the treatment
of HCV infection is burdened by adverse reactions in at
least 10% of patients [2]. Moreover, a sustained virological
response is achieved in only 50% of patients infected with
HCV genotype 1 [3]. PegIFN/RBV treatment failure is
mainly attributed to its low efficacy against genotypes 1
and 4, but also, to some extent to its side effects [3,4].
Recently developed direct-acting antiviral agents (DAAs)
are predicted to have a major impact both in combination* Correspondence: f.baldanti@smatteo.pv.it
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stated.with PegIFN/RBV, as well as in IFN-free regimens and
telaprevir and boceprevir have now been approved as
standard of care treatment [5]. Targets for DAA include
HCV NS3 protease, NS5B polymerase and NS5A protein
which are essential for virus replication. [6-12].
Nevertheless, the combination of a high HCV replica-
tion rate, the low fidelity of HCV polymerase and selective
pressures by the immune system and drug treatment lead
to the in vivo development of viral quasispecies with high
sequence diversity among various genotypes and subtypes
[13,14] with the potential accumulation of virus variants
showing mutations with varying degrees of resistance to
DAAs [11-13,15-22], even in the absence of pre-existing
drug-exposure [17,23-26]. In particular, natural changes in
HCV NS5A and NS5B amino acids (aa) associated with
reduced drug susceptibility have been observed in treat-
ment naïve patients [17,27,28].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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resistant variants in HCV NS5A and NS5B from DAA-
naïve patients infected with genotypes 1a or 1b HCV
strains.
Materials and methods
HCV DAA-naive patients referred to our hospital between
2011 and 2012 were included in this study. A comparable
number of sequential patients infected with HCV geno-
types 1a or 1b was considered in the analysis. From each
patient, serum samples were prospectively collected fol-
lowing approval of the study by the Ethics Committee of
the Fondazione IRCCS Policlinico San Matteo (protocol
no. 20080009620) and after obtaining written informed
consent. HCV genotypes were defined using the Versant
HCV Genotype 2.0 Assay LiPA (Siemens Healthcare
Diagnostic Inc., Tarrytown, NY USA). NS5A and NS5B
sequencing was used to differentiate HCV genotypes 1a
and 1b. Data were analyzed with the Blast program
(http://blast.ncbi.nlm.nih.gov).
Viral RNA was extracted from serum samples using the
automatic Easy Mag extractor (Biomerieux, Lyon, France),
and full-length HCV NS5A and NS5B genes were ampli-
fied using Superscript III One-step enzyme with PlatinumTable 1 Amplification and sequencing primers for HCV NS5A
Gene Primer name
GT1a* NS5A HCV-1a NS5A Fwd out
HCV-1a NS5A Rew out
HCV-1a NS5A Fwd inn
HCV-1a NS5A Rew inn
HCV-1a NS5A Rew Seq
HCV-1a NS5B Fwd out
GT1a* NS5B HCV-1a NS5B Rew out
HCV-1a NS5B Fwd inn
HCV-1a NS5B Rew inn
HCV-1a NS5B Fwd Seq
HCV-1a NS5B Rew Seq
HCV-1b NS5A Fwd out
HCV-1b NS5A Rew out
HCV-1b NS5A Fwd inn
GT1b§ NS5A HCV-1b NS5A Rew inn
HCV-1b NS5A Fwd Seq
HCV-1b NS5B Fwd out
HCV-1b NS5B Rew out
HCV-1b NS5B Fwd inn
GT1b§ NS5B HCV-1b NS5B Rew inn
HCV-1b NS5B Fwd Seq2
HCV-1b NS5B Rew Seq3
*Genotype 1a; §Genotype 1b.Taq (Invitrogen, Carlisbad, CA, USA) in a nested RT-PCR.
Primers used in the RT-PCR and nested PCR, spanning
NS5A aa 1 to 406 and NS5B aa 1 to 547, are shown in
Table 1. The PCR products in the first PCR round were
obtained by using the following conditions: 30′ at 45°C for
the reverse transcription followed by 10′ at 94°C, and then
50 cycles at 94°C for 1′, 60°C for 1′ and 68°C for 2′, with
an extension at 68°C for 10′ in all reactions. Three micro-
liters from the first PCR reaction were used in the nested
PCR with the following conditions: denaturation step at
94°C for 10′ and then 30 cycles at 94°C for 1′, 60°C for 1′
and 72°C for 2′, with an extension at 72°C for 10′in the
NS5A gene; and denaturation step at 94°C for 10′ and
then 30 cycles at 94°C for 1′, 65°C for 1′ and 72°C for 2′,
with an extension at 72°C for 10′ in the NS5B gene.
Direct sequencing of PCR products was performed
using an automatic sequencer (ABI PRISM 3100 genetic
analyzer DNA Sequencer, Applied Biosystems, Foster
City, CA, USA) and the BigDye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA,
USA). Sequencing primers used to complete the NS5A
and NS5B analyses are shown in Table 1.
Nucleotide sequences were assembled using the Sequen-
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ence sequences of different subtypes. GeneBank accession
numbers for NS5A and NS5B reference sequences are
AF009606 for HCV genotype 1a, and AY045702 for geno-
type 1b.
The sequences reported in this study have been submit-
ted to the GenBank database under accession numbers
KF667756 - KF667879.
Results
The clinical and virological characteristics of the patients
considered in the study are provided in Table 2. Most
patients (26/32, 81%) were naive to PegIFN and RBV,
while none had ever been treated with HCV NS3, NS5A
or NS5B inhibitors. Ten out of 62 (16.2%) patients were
co-infected with HIV and under treatment with highly
active antiretroviral therapy (HAART), while 52/62 (83.8)
were HCV mono-infected (Table 2).
DAA resistance mutations were detected in both geno-
types 1a and 1b strains from DAA naïve HCV patients
(Table 3 and Table 4). Overall, the median frequency of
single mutations was 4.75% (range 3.1% and 36.6%). In
detail, in genotype 1a strains, mutations in the NS5A re-
gion associated with resistance to Daclatasvir, Ledipasvir
and GSK805 were observed in 4/32 (12.5%) patients
(Table 3); mutations in the NS5B region associated with
resistance to PSI-352938, Filibuvir and Tegobuvir were
observed in 4/32 (12.5%) patients (Table 4). In genotype
1b strains, mutations in the NS5A region associated with
resistance to Daclatasvir, Samatasvir, Ledipasvir and
GSK805 were observed in 16/30 (53.3%) patients (Table 3);
mutations in the NS5B region associated with resistance
to Sofosbuvir, Mericitabine, PSI-352938, Tegobuvir, HCV-
796, Filibuvir, JTK-109 and Deleobuvir were observed in
27/30 (90%) patients (Table 4). Of note, the mutation
V499A was constitutively present in NS5B of all genotype









No. of HIV-1/HCV co- infected patients receiving HAART
Median HCV viral load (UI/ml) in HCV mono-infected patients 1,6
Median HCV viral load (UI/ml) in HCV/HIV co-infected patients 2,3
No. of patients naïve to peg IFN/RBV
HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; HAART, Highly Active Agenotype 1b strains. Overall, HCV NS5A and NS5B resist-
ance mutations in HCV mono-infected patients were
found in 30/62 (48.3%) patients.
HCV NS5A and NS5B resistance mutations in HCV/
HIV co-infected patients were found in 3/10 (30%) pa-
tients with no statistical difference vs mono-infected pa-
tients (p = 0.32). In detail, one patient had the M28V
mutation in NS5A, one patient had Y448H in NS5B and
one patient had H58P + Y452H in NS5A and NS5B,
respectively.
Among the 30 patients infected with genotype 1b
strains, two (6.6%) had a mixture of virus variants carrying
multiple NS5A resistance mutations, while eight (26.6%)
exhibited a mixture of strains with multiple NS5B resist-
ance mutations. In detail, in NS5A of two patients carry-
ing genotype 1b, the mixture Q54H+ Y93H was observed.
In NS5B of eight patients with genotype 1b, eight differ-
ent mixtures were observed (L159F + V499A; L159F +
C316N; L159F+C316N+V499A; L159F+C316N+M426L;
C316N+M426L; C316N+V499A; V321I + V499A and
C316N+ R465G+V499A). In addition, combinations of
multiple resistance variants in both the NS5A and NS5B
genes of the same HCV strain, were observed in 1/32
(3.1%) patients with HCV genotype 1a and 8/30 (26.6%)
patients with HCV genotype 1b. In particular, a patient
with genotype 1a infection had the H58P mutation in
NS5A and Y452H in NS5B, while in the eight patients
carrying genotype 1b, 3 patients had Q54H in NS5A
and C316N in NS5B, one patient had L31M in NS5A and
C316N in NS5B, one patient had L31M in NS5A and
Y452H in NS5B, one patient had Q54H + Y93H in NS5A
and C316N+V499A in NS5B, one patient had Q54H in
NS5A and L159F in NS5B and one patient had Q54H in
NS5A and L159F + C316N in NS5B.
Notably, all aa variants detected in DAA-naïve patients
were low-level resistance mutations except for the muta-
tion Y448H found in the NS5B gene of 1/32 (3.1%) HCVV genotype (no. of patients)
1a (n = 32) 1b (n = 30)
22 (68.7%) 17 (56.6%)
10 (31.2%) 13 (43.3%)
31 (96.8%) 25 (83.3%)
1 (3.1%) 5 (16.6%)
8 (25%) 2 (6.6%)
14,064 (range 6,743-7,985,320) 991,975 (range 3,470-4,381,000)
67,635 (range 46,801-7,985,320) 473,597 (range 46,801-900,393)
26 (81.2%) 29 (96.6%)
nti-Retroviral Therapy; IFN, Interferon; RBV, Ribavirin.
Table 3 Amino acid mutations in the HCV NS5A protein in DAA-naïve patients infected with HCV genotypes 1a (n = 32)
or 1b (n = 30)
DAAs NS5A mutations in DAA-naïve patients
Genotype 1a Fold change in EC50 Genotype 1b Fold change in EC50 References
Daclatasvir M28V (1/32, 3.1%)α 1.3 L28M/V (1/30,3.3%) 2.0 [15,17,19]
Q30E/H/R/K R30H
Daclatasvir L31M/(1/32, 3.1%) 341 L31M (2/30, 6.6%) 3 [15,17,19]
Ledipasvir L31M/(1/32, 3.1%) 140 L31M [29]
GSK805 L31M/(1/32, 3.1%) >150 L31M [30]
Samatasvir L31M L31M (2/30, 6.6%) 3.6 [31]
P32L P32L
Daclatasvir Q54H/L/N Q54H (8/30, 26.6%) 1.0 [19]
Daclatasvir H58P (2/32, 6.2%) 1.2 P58S/T/L [19]
N69T N69T
A92V A92V
Daclatasvir Y93C/H/N Y93H (3/30, 10%) 24 [15,17,19]
Ledipasvir Y93C/H/N Y93H (3/30, 10%) 1319 [29]












αAmino acid changes conferring resistance to NS5A inhibitors are reported in italics. The number and % of patients with mutated strains is reported in brackets.
GeneBank accession number of NS5A reference sequence for HCV genotype 1a is AF009606, and for genotype 1b, AY045702.
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http://www.virologyj.com/content/10/1/355genotype 1a strains which confers higher-level resistance
to Tegobuvir and Y93H observed in NS5A of 3/30 (10%)
HCV genotype 1b strains which confers higher-level resist-
ance to Daclatasvir, Ledipasvir and Samatasvir.
Discussion
In this study, 62 patients with genotype 1a or 1b HCV
strains were evaluated to determine the frequency of
HCV DAA-resistant variants in patients naïve to DAA
treatment. The identification of baseline resistance mu-
tations to anti-HCV inhibitors is crucial for defining
new therapeutic approaches. Relevant natural aa polymor-
phisms were found in genotypes 1a and 1b. Some major
resistance mutations and other mutations conferring low
level resistance to NS5A HCV inhibitors (Daclatasvir,
Ledipasvir, GSK805 and Samatasvir), as well as nucleo-
sides (Sofosbuvir, Mericitabine, and PSI-352938) and
non-nucleosides (Tegobuvir, Filibuvir, HCV-796, JTK-109 and Deleobuvir) were observed. Similarly, resist-
ance mutations to NS5B HCV inhibitors were confirmed
in DAA naïve patients with HCV genotypes 1a and 1b
[11,12,17,19,25,29-32,35,36]. Among major mutations in
the NS5A gene conferring high level resistance to NS5A
inhibitors [17,19,30,31], Q30E/H/K and Y93N/C were not
observed, while L31M and Y93H were detected in 2 and 3
patients respectively. A major mutation in the NS5B gene
S282T which confers high level resistance to polymerase
nucleotide inhibitors [8,17,37], was not observed, while
Y448H associated with reduced susceptibility to NS5B
non-nucleoside polymerase inhibitors was detected in one
patient. Resistance mutations were not observed more
frequently in HCV/HIV co-infected patients than in
HCV mono-infected patients.
Overall, the median frequency of single mutations
observed in the NS5A and NS5B genes analyzed was low
as reported in other geographical regions [17,27,28]. In
Table 4 Amino acid mutations in the HCV NS5B protein in DAA-naïve patients infected with HCV genotypes 1a (n = 32)
or 1b (n = 30)
NS5B mutations in DAA-naïve patients
DAAs Genotype 1a Fold change in EC50 Genotype 1b Fold change in EC50 References
S96Tγ S96T
N142T N142T




PSI-352938 V321I (1/32, 3.1%)α 2.0 V321I (1/30, 3.3%) 2.0 [17,33]








Filibuvir M426L (1/32, 3.1%) 0.8 M426L (2/30, 6.6%) 0.8 [21]
C445F C445F
Tegobuvir Y448H (1/32, 3.1%) 36.0 Y448H [34]
Tegobuvir Y452H (1/32, 3.1%) 6.9 Y452H (1/30, 3.3%) 6.9 [34]










αAmino acid changes conferring resistance to NS5B inhibitors are reported in italics. The number and % of patients with mutated strains is reported in brackets.
βResistance levels are reported only when associated with L320F. GeneBank NS5B reference sequence accession number for HCV genotype 1a is AF009606, and
for genotype 1b, AY045702.
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http://www.virologyj.com/content/10/1/355addition, the prevalence of patients with resistance muta-
tions in both genes at baseline was lower in HCV genotype
1a than in HCV genotype 1b infected patients. The higher
prevalence of mutations in genotype 1b is due to the
presence of C316N, which confers low level resistance
to Tegobuvir and HCV-796 in most genotype 1b strains.
In addition, in HCV genotype 1b infected patients, the
frequency of multiple variant combinations was lower
in NS5A than in NS5B. Moreover, in HCV genotype 1a
infected patients, combinations of multiple resistance
mutations in both NS5A and NS5B of single patients
were observed with significant frequency in both HCV
genotype 1a and 1b infected patients. It should beunderlined that while the Q54H + Y93H combination
has already been reported [19] to provide moderate resist-
ance to Daclatasvir, the other combinations have never
been investigated, and their level of resistance is not
known. In general, greater heterogeneity was confirmed in
HCV genotype 1b strains [26,27].
Only 3.1% of patients with HCV genotype 1a and
10% with HCV genotype 1b had viral strains with mu-
tations conferring higher-level resistance to Tegobuvir,
Daclatasvir, Samatasvir Ledipasvir and GSK805. Although
the presence of preexisting single or double mutations
might not confer a significant level of resistance or pre-
clude successful treatment as observed in PI treatment
Paolucci et al. Virology Journal 2013, 10:355 Page 6 of 7
http://www.virologyj.com/content/10/1/355[23], baseline resistance should be taken into consider-
ation in the prospect of HCV IFN-free DAA therapy. Of
particular interest are patients carrying combinations of
multiple resistance mutations in both the NS5A and
NS5B genes, which might increase the possibility of fail-
ure in patients treated with multiple DAA containing
regimens.
Further studies are needed to better evaluate the role
of all variants and the influence which they might have
in modulating resistance levels or susceptibility to HCV
drugs.
The sustained response in most patients, even when
carrying DAA baseline resistance, is probably due to the
clearance of HCV. Although there is the possibility that
baseline resistant variants may result in viral break-
throughs during treatment [20,27,29], the clinical impact
of resistance-mutations in DAA-naïve patients and their
influence on the ability of the virus to replicate in vivo
remain unclear [14,17,25]. Thus, for patients receiving
DAA interferon free regimens, or those who will receive
in the near future only combined classes of HCV inhibi-
tors, the potential role of DAA-resistant variants prior to
treatment should be evaluated in all target genes since
their clinical relevance could be useful in the management
of new HCV therapies.
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